APTAMER GROUP PLC

Report Publication Announcement • Nov 3, 2025

National Storage Mechanism | Additional information

RNS Number : 7690F

Aptamer Group PLC

03 November 2025

3 November 2025

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Posting of Annual Report and Accounts and Notice of Annual General Meeting

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announces that the Annual Report and Accounts for the year ended 30 June 2025 and Notice of its 2025 Annual General Meeting (AGM) were posted to shareholders today. These documents are available on the Company's website at https://aptamergroup.com/.

Aptamer will host its AGM at 11:00 GMT on 27 November 2025 at Windmill House, Innovation Way, York, YO10 5BR.  The AGM will be held in person only and there will be no new information presented at the meeting.

The results of voting on all resolutions at the AGM will be announced to the London Stock Exchange and the full results of the voting published on the Company's website, as soon as practicable after the conclusion of the AGM.

- Ends -

For further information, please contact: 

Aptamer Group plc   Dr Arron Tolley, Chief Executive Officer	+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser     Andrew Emmott	+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker     James Pope / Andrew Thacker	+44 (0) 20 3657 0050
Northstar Communications Limited - Investor Relations Sarah Hollins	+44 (0) 113 730 3896

About Aptamer Group

Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAEAXEFDEDSFFA